TORONTO, Dec. 29, 2017 (GLOBE NEWSWIRE) — Canada House Wellness Group Inc. (CSE:CHV) (“Canada House” or the “Company”) announces that Gerry Goldberg will be retiring as the Company’s Interim CEO with effect from January 1, 2018.

The Company wishes to thank Mr. Goldberg for his services, including but not limited to, his assistance in accomplishing the Company’s merger with Marijuana for Trauma in late 2016, and with subsequent financings.

“I have really enjoyed working alongside the Company’s executive team this past year, applauding its constructive approach to both challenges and opportunities.  I’m also a shareholder, and stand ready to assist you all in any way I can as the Company moves into the New Year with its abundance of opportunities in this exciting cannabis industry!” Mr. Goldberg stated.

After accepting Mr. Goldberg’s retirement request, the Board requested that Executive Chairman Larry Bortles become the Company’s CEO and Chairman, which he accepted.

Canada House Wellness Group Inc.

Canada House is the parent company of Marijuana for Trauma Inc., Knalysis Technologies and Abba Medix Corp. The Company’s goal is to become a marketplace leader through strategic partnerships, mergers, and acquisitions to create a fully integrated cannabis therapy company. For more information please visit or

Cautionary Statement Regarding Forward‐Looking Information. Certain statements within this news release pertaining to the Company constitute “forward‐looking statements”, within the meaning of applicable securities laws, including without limitation, statements regarding future estimates, business plans and/or objectives, sales programs, forecasts and projections, assumptions, expectations, and/or beliefs of future performance, are “forward‐looking statements”. Such “forward‐looking statements” involve known and unknown risks and uncertainties that could cause actual and future events to differ materially from those anticipated in such statements. Forward‐looking statements include, but are not limited to, statements with respect to the anticipated effects of the financing, regulatory changes, timeliness of government approvals for the granting of permits and licenses, changes in medical marijuana prices, actual operating performance of facilities, competition and other risks affecting the Company in particular and the medical marijuana industry generally, including those set out in the Company’s public disclosure record. The Company assumes no responsibility to update or revise forward‐looking information to reflect new events or circumstances unless required by law.

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.